Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.

Abstract

The clinical efficacy of peramivir in the treatment of severe seasonal influenza in critically ill patients admitted to an intensive care unit (ICU) is not well established. The aim of this study was to compare the clinical efficacy of peramivir with that of oseltamivir in such critically ill patients. From September 2010 through March 2014, sixty patients with influenza confirmed by RT-PCR and hospitalized in our ICU were enrolled and reviewed retrospectively. Thirty-four and twenty-six patients received initial peramivir and oseltamivir, respectively. The median sequential organ failure assessment score was higher in the patients treated with peramivir (11 vs. 8.5, P= 0.029). There was no significant difference between the two groups in the median duration of use of antiviral agents. There were also no significant differences between the groups in 14-day (17.6% in peramivir vs. 7.7% in oseltamivir, P = 0.446), or 28-day mortality (35.3% in peramivir vs. 34.6% in oseltamivir, P = 0.813) or in the median length of ICU stay (11 days in peramivir vs. 12 days in oseltamivir, P=0.852). Peramivir has the similar clinical efficacy to oseltamivir in the treatment of severe seasonal influenza in the critically ill patients admitted to ICU.

• Authors: Jung-Wan Yoo, Sang-Ho Choi, Jin Won Huh, Chae-Man Lim, Younsuck Koh, Sang-Bum Hong
• Journal: Journal of medical virology (J Med Virol) Vol. 87 Issue 10 Pg. 1649-55 (Oct 2015) ISSN: 1096-9071 [Electronic] United States
• PMID: 25946636 (Publication Type: Journal Article)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Acids, Carbocyclic
• Antiviral Agents
• Cyclopentanes
• Guanidines
• Oseltamivir
• peramivir

Topics

• Acids, Carbocyclic
• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Antiviral Agents (administration & dosage, therapeutic use)
• Critical Illness
• Cyclopentanes (administration & dosage, therapeutic use)
• Guanidines (administration & dosage, therapeutic use)
• Humans
• Influenza A Virus, H1N1 Subtype
• Influenza, Human (drug therapy, mortality)
• Intensive Care Units (statistics & numerical data)
• Length of Stay (statistics & numerical data)
• Middle Aged
• Organ Dysfunction Scores
• Oseltamivir (administration & dosage, therapeutic use)
• Retrospective Studies
• Seasons
• Time Factors
• Treatment Outcome
• Young Adult